Pharmacyclics Llc Company Profile

✉ Email this page to a colleague

PHARMACYCLICS LLC has three approved drugs.

There are fifty-four US patents protecting PHARMACYCLICS LLC drugs.

There are three hundred and fifty-one patent family members on PHARMACYCLICS LLC drugs in forty-seven countries and thirty-four supplementary protection certificates in fifteen countries.

International Patents:	351
US Patents:	54
Tradenames:	1
Ingredients:	1
NDAs:	3
Patent Litigation for Pharmacyclics Llc:	See patent lawsuits for Pharmacyclics Llc

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-002	Feb 16, 2018		RX	Yes	No	9,795,604*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No	9,181,257*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	10,004,746*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-002	Feb 16, 2018		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes	8,999,999*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	9,801,881*PED	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	70 mg	➤ Subscribe	2018-12-14
➤ Subscribe	Tablets	280 mg and 420 mg	➤ Subscribe	2018-12-14
➤ Subscribe	Tablets	140 mg and 560 mg	➤ Subscribe	2018-11-05

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Brazil	112014030424	⤷ Sign Up
Spain	2673973	⤷ Sign Up
Australia	2020202752	⤷ Sign Up
Eurasian Patent Organization	201492082	⤷ Sign Up
Japan	6869400	⤷ Sign Up
Eurasian Patent Organization	018573	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2201840	15C0029	France	⤷ Sign Up	PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2526934	273 5026-2016	Slovakia	⤷ Sign Up	PRODUCT NAME: IBRUTINIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/945 20160530
2201840	233 5006-2015	Slovakia	⤷ Sign Up	PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023
2201840	CR 2015 00021	Denmark	⤷ Sign Up	PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023
2201840	2015/020	Ireland	⤷ Sign Up	PRODUCT NAME: IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/945 20141021
2529621	132017000036530	Italy	⤷ Sign Up	PRODUCT NAME: IBRUTINIB O SUO SALE FARMACEUTICAMENTE ACCETTABILE(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/4/945, 20150707
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.